Biosimilar Monoclonal Antibodies Mabs Market By Product Type (Rituximab Biosimilars, Infliximab Biosimilars, Trastuzumab Biosimilars, Adalimumab Biosimilars, Bevacizumab Biosimilars), Application (Oncology, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals, Clinics, Research Institutes) & Region for 2024-2031

Biosimilar Monoclonal Antibodies Mabs Market Valuation – 2024-2031

Rising healthcare costs and the prevalence of chronic diseases are driving the demand for cost-effective biologic treatments. Given the high cost of original biologic medications, biosimilars provide a more cheap option without sacrificing efficacy or safety. Governments and healthcare providers are increasingly using biosimilars to help manage healthcare costs and increase patient access to innovative medicines driving the market growth surpassing USD 6.17 Billion in 2024 and reaching USD 17.23 Billion by 2031.

Furthermore, regulatory bodies around the world are expediting biosimilar approval processes, accelerating market penetration. As a result, the market for biosimilar mAbs is increasing, driven by economic incentives and the urgent need for affordable healthcare solutions is expected to grow at a CAGR of about 15.10% from 2024 to 2031.

Biosimilar Monoclonal Antibodies Mabs MarketDefinition/ Overview

Biosimilar monoclonal antibodies (mAbs) are biologic products that are extremely similar to an already approved reference mAb, with no clinically significant changes in terms of safety, purity, or potency. They are used to treat a variety of ailments, including cancer, autoimmune disorders, and infectious diseases, and offer a low-cost alternative to pricey original biologic medicines. Biosimilar mAbs are used in oncology, rheumatology, gastroenterology, and other therapeutic areas where mAbs are commonly used. The future of biosimilar mAbs seems positive, because to rising healthcare demand, regulatory support, and continued science developments. As patents for original mAbs expire, the market for biosimilars is likely to grow, increasing access to life-saving medicines while lowering healthcare costs worldwide.

Will Increasing Demand for Biologic Therapies Drive the Biosimilar Monoclonal Antibodies Mabs Market?

The growing need for biologic medicines, particularly monoclonal antibodies (mAbs), is a key driver of the biosimilar mAbs market. Biologic therapies have transformed the treatment landscape for a variety of chronic and complex diseases, providing focused and frequently more effective options than traditional medications. Several causes contribute to this rise in demand, highlighting biosimilar mAbs’ growth trajectory.

Biologic medicines, particularly monoclonal antibodies, are increasingly chosen due to their specificity in targeting disease pathways. They play an important role in treating cancer, autoimmune disorders, and inflammatory diseases. As these medicines become increasingly common in clinical practice, the demand for cost-effective alternatives, such as biosimilar mAbs, grows to relieve the financial strain on healthcare systems and patients alike. According to a RAND Corporation analysis from 2023, biosimilars in the United States are priced 15-35% lower than reference pharmaceuticals on average. The Centers for Medicare and Medicaid Services (CMS) claimed that biosimilars saved Medicare $7.9 billion in 2022, with a projected savings of $130 billion by 2025.

The patent expiration of original biologic mAbs creates opportunity for biosimilar makers. As patents expire, biosimilar producers can join the market with products that are as effective, safe, and high-quality as their originator counterparts, but at a lower cost. This competition lowers prices, improves market accessibility, and increases patient access to vital medications.

Regulatory support and developing guidelines are critical in promoting the use of biosimilar mAbs. Regulatory bodies, such as the FDA in the United States and the EMA in Europe, have built rigorous approval routes for biosimilars. These methods include rigorous comparability studies to demonstrate resemblance to the reference product, which ensures that biosimilar mAbs meet demanding safety and efficacy standards before entering the market. As of March 2024, the FDA had approved 41 biosimilars, including 14 oncology-related mAbs. The approval rate has grown by 25% over the previous year, demonstrating greater regulatory backing.

Healthcare policy and reimbursement schemes are progressively promoting the use of biosimilars to reduce healthcare costs. Governments and insurers are promoting the use of biosimilar mAbs through price and reimbursement rules that encourage healthcare providers to recommend these cost-effective alternatives. This strategic approach promotes greater market adoption and speeds up the introduction of biosimilar mAbs into clinical practice. In Europe, the European Commission’s 2024 report on biosimilar market development found that biosimilars had resulted in price reductions of up to 60% for some monoclonal antibodies, greatly enhancing cost-effectiveness in healthcare systems.

In January 2024, According to a report published in Nature Biotechnology, the worldwide biologic medicine market will be worth USD 420 Billion by 2025, with biosimilars estimated to account for 30% of that market by 2030.

Will Rising Growing Stringent Approval Process Hamper the Biosimilar Monoclonal Antibodies Mabs Market?

The rising stringency of regulatory processes may provide problems for the biosimilar monoclonal antibodies (mAb) market. Regulatory authorities around the world, such as the FDA in the United States and the EMA in Europe, require biosimilar manufacturers to demonstrate resemblance to reference products in terms of quality, efficacy, and safety. These strict licensing processes include thorough analytical and clinical studies, which can necessitate a large investment of time, resources, and experience from biosimilar producers.

Stringent approval processes may cause a delay in market introduction for biosimilar mAbs. Manufacturers must traverse intricate regulatory paths, which can lengthen the time to market and raise development expenses. This delay may impede timely access to cost-effective biosimilar alternatives, reducing the market’s capacity to offer competitive pricing and expand patient access to biologic medicines.

Furthermore, the complexity and variety of regulatory requirements across regions can make market entry efforts for biosimilar mAbs more challenging. Variations in regulatory expectations and the necessity for additional data submissions might increase overall development costs and durations. As a result, certain biosimilar producers may struggle to achieve competitive price and profitability, limiting their capacity to effectively compete with originator biologics in the market.

Category-Wise Acumens

Will Rising Demand for Rituximab Biosimilars Propel the Biosimilar Monoclonal Antibodies Mabs Market?

The growing demand for Rituximab biosimilars is expected to boost the biosimilar monoclonal antibodies (mAbs) market significantly. Rituximab biosimilars are gaining popularity due to its efficacy in treating a variety of malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune illnesses like rheumatoid arthritis. The original Rituximab, commercialized by Genentech and Biogen under the brand name Rituxan, was a cornerstone of these therapy. As Rituxan’s patents expired, biosimilars hit the market, providing comparable therapeutic effects at a cheaper cost. This cost benefit is critical for healthcare systems and people, especially in areas with tight healthcare resources.

Global regulatory bodies are rapidly approving Rituximab biosimilars, which is boosting market expansion. For instance, in January 2024, the European Medicines Agency (EMA) approved a new Rituximab biosimilar for use in the EU. These approvals are based on rigorous clinical trials that show biosimilars are safe, effective, and of high quality, guaranteeing they satisfy the same requirements as their reference products. The increasing number of approvals expands the availability of Rituximab biosimilars in diverse areas, increasing their uptake.

The economic benefits of Rituximab biosimilars are significant. They offer significant cost reductions over the original biologic, making them an appealing alternative for healthcare providers and patients. For instance, in March 2024, a study released found that the use of Rituximab biosimilars in the United States might save the healthcare system billions of dollars over the next decade. These savings can be reinvested in other areas of healthcare, thereby enhancing patient care and access to breakthrough treatments.

On the other hand, Adalimumab biosimilars are the fastest growing group, thanks to their widespread usage in the treatment of autoimmune disorders such as rheumatoid arthritis, Crohn’s disease, and psoriasis. The rising prevalence of these illnesses, combined with a significant demand for low-cost therapy choices, is driving the rapid expansion of Adalimumab biosimilars.

Will Rising Usage of Oncology Biosimilars Drive the Biosimilar Monoclonal Antibodies Mabs Market?

The increasing use of cancer biosimilars is expected to fuel significant growth in the biosimilar monoclonal antibodies (mAb) industry. Oncology biosimilars, such as Rituximab, Trastuzumab, and Bevacizumab, provide significant cost savings and increased access to treatment for patients with various forms of cancer. Cost-effectiveness is a significant motivator. Original biologic mAbs used in oncology are frequently expensive medicines, putting a major financial strain on healthcare systems and patients. Biosimilar mAbs, which are very similar and therapeutically equal to their reference medicines, usually enter the market at lower pricing due to lower development costs and competition. For instance, the development of Rituximab biosimilars has been found to drastically reduce treatment costs, making oncology treatments more inexpensive and accessible to a broader patient population.

According to a 2023 study by the American Society of Clinical cancer (ASCO), the launch of biosimilar versions of cancer mAbs resulted in an average cost decrease of 30-40% compared to their reference products. This considerable cost savings is driving adoption throughout the healthcare system.

Oncology biosimilars are being adopted in response to regulatory approvals and guidelines. Regulatory authorities throughout the world, including the FDA in the United States and the EMA in Europe, have developed comprehensive routes for approving biosimilars based on rigorous comparability studies that demonstrate similarity to the reference product. These approvals boost confidence in biosimilar mAbs’ safety, efficacy, and quality, encouraging healthcare professionals to use them in clinical practice.

The United States Food and Drug Administration (FDA) has been actively approving oncology biosimilars. As of March 2024, the FDA had authorized 41 biosimilars, 14 of which were oncology-related. In 2023 alone, the FDA authorized 5 new cancer biosimilars, underscoring the agency’s commitment to growing the biosimilar market.

Healthcare legislation and activities targeted at lowering healthcare costs are fueling the use of oncology biosimilars. Governments and insurers are progressively promoting the adoption of biosimilars through pricing and reimbursement regulations. For example, in some countries, hospitals and healthcare practitioners are paid more for prescribing biosimilars over their branded counterparts, which encourages their use in oncology settings.

The fastest-growing application, on the other hand, is for autoimmune illnesses. The rising prevalence of autoimmune illnesses such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease has increased demand for biosimilar monoclonal antibodies like Adalimumab and Infliximab. These biosimilars give effective treatment alternatives at a fraction of the cost of their branded counterparts, making them a popular choice among healthcare professionals and patients, boosting market growth.

Gain Access into Biosimilar Monoclonal Antibodies MabsMarket Report Methodology

Country/Region-wise

Will Rising Adoption of Biosimilars in Europe Drive the Biosimilar Monoclonal Antibodies Mabs Market?

The increasing acceptance of biosimilars in Europe is expected to considerably drive the biosimilar monoclonal antibodies (mAbs) industry. Europe’s well-established regulatory structure, led by the European Medicines Agency (EMA), has created an enabling climate for biosimilars. The EMA’s rigorous approval procedure guarantees that biosimilars satisfy high criteria of safety, efficacy, and quality, establishing trust among healthcare providers and patients.

The economic benefits of biosimilars are a primary driving force behind their acceptance in Europe. Biosimilars provide significant cost savings over their reference biologics, making them an appealing alternative for healthcare systems looking to save costs. These savings can be used to fund other vital areas of healthcare, resulting in better overall patient care. For Instance, In March 2024, the UK National Health Service (NHS) reported significant savings from the use of biosimilars, allowing resources to be allocated to novel treatments and expanding patient access to biologic therapy.

Healthcare providers in Europe are increasingly recognizing biosimilars’ therapeutic equivalence with their reference products. Clinical trials and real-world evidence have shown that biosimilars deliver the same clinical advantages as original biologics, hence increasing their popularity among physicians and patients. In April 2024, The European Crohn’s and Colitis Organisation (ECCO) approved the use of biosimilar mAbs to treat inflammatory bowel disease, citing strong clinical evidence supporting their efficacy and safety.

Furthermore, strategic alliances and partnerships in the European biosimilar industry are hastening the development and commercialization of biosimilar antibodies. Pharmaceutical businesses are collaborating to exploit their pooled experience and resources, thereby increasing their competitive advantage.

Will Increasing Healthcare Expenditure in Asia-Pacific Propel the Biosimilar Monoclonal Antibodies Mabs Market?

The growing healthcare expenditure in Asia-Pacific is expected to significantly boost the market for biosimilar monoclonal antibodies (mAbs). As governments in this region invest more in healthcare infrastructure and services, there is an increasing demand for low-cost, effective therapies. Governments are promoting healthcare accessibility, which is accelerating the use of low-cost biosimilars. For instance, in January 2024, India’s government announced a significant increase in its healthcare budget, with monies explicitly allocated to boost access to biologic and biosimilar medications for its citizens.

The growing healthcare expenditure in Asia-Pacific is expected to significantly boost the market for biosimilar monoclonal antibodies (mAbs). As governments in this region invest more in healthcare infrastructure and services, there is an increasing demand for low-cost, effective therapies. Governments are promoting healthcare accessibility, which is accelerating the use of low-cost biosimilars. In January 2024, For example, India’s government announced a significant increase in its healthcare budget, with monies explicitly allocated to boost access to biologic and biosimilar medications for its citizens.

Regulatory support in Asia-Pacific is also driving the biosimilar mAbs market. Countries such as Japan, South Korea, and Australia have built regulatory mechanisms to enable biosimilar approval and commercialization. In February 2024, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved a new biosimilar mAb for cancer therapy, demonstrating the region’s commitment to incorporating biosimilars into its healthcare system. Such regulatory developments are encouraging more companies to invest in and develop biosimilar drugs, accelerating market growth.

Competitive Landscape

The competitive landscape of the biosimilar monoclonal antibodies (mAbs) market is characterized by the presence of numerous smaller and emerging biotechnology companies striving to develop and commercialize biosimilar mAbs. These companies often focus on niche therapeutic areas and leverage partnerships with contract research organizations (CROs) and contract manufacturing organizations (CMOs) to expedite development and reduce costs. Additionally, various regional players in emerging markets are intensifying competition by producing cost-effective biosimilars to meet local demand. Strategic collaborations, regulatory support in biosimilar approvals, and advancements in bioprocessing technologies further enhance the competitive dynamics of this rapidly evolving market.

Some of the prominent players operating in the biosimilar monoclonal antibodies mabs market include

• AbbVie, Inc.
• Amgen, Inc.
• Biocon Limited
• Coherus BioSciences Inc.
• Merck KGaA
• Novartis AG
• Pfizer, Inc.
• Samsung Bioepis Co. Ltd.
• Sanofi S.A.

Latest Developments

• In January 2024, Amgen and Allergan announced the launch of ABP 798, a biosimilar to Rituxan (rituximab), in the United States. This breakthrough is a crucial step toward increasing access to cheap cancer and autoimmune disease medicines.
• In February 2024, Samsung Bioepis got approval from the European Medicines Agency (EMA) for its biosimilar candidate SB11, a biosimilar to Lucentis (ranibizumab), which is used to treat retinal diseases. This approval broadens Samsung Bioepis’ offering in the ophthalmology sector.
• In March 2024, Celltrion Healthcare introduced Yuflyma (CT-P17), a biosimilar to Humira (adalimumab), in the European market. Yuflyma is notable as the first high-concentration, citrate-free copycat of Humira, providing patients with a more convenient and less unpleasant treatment choice.
• In April 2024, Biocon Biologics gained FDA clearance for MYL-1401O, a biosimilar to Herceptin (trastuzumab), which is used to treat HER2-positive breast cancer. This approval broadens Biocon Biologics’ oncology range and boosts its position in the United States market.

Report Scope

Biosimilar Monoclonal Antibodies Mabs Market, By Category

 Product Type

• Rituximab Biosimilars
• Infliximab Biosimilars
• Trastuzumab Biosimilars
• Adalimumab Biosimilars
• Bevacizumab Biosimilars

Application

• Oncology
• Autoimmune Diseases
• Infectious Diseases

 End-User

• Hospitals
• Clinics
• Research Institutes

Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report</h